title: SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago).
abstract: SP-303, a large proanthocyanidin oligomer isolated from the latex of the plant species Croton lechleri (Eupborbiaceae) has demonstrated broad activity against a variety of DNA and RNA viruses. In cell culture, SP-303 exhibits potent activity against isolates and laboratory strains of respiratory syncytial virus (RSV), influenza A virus (FLU-A) and parainfluenza virus (PIV). Parallel assays of SP-303 and ribavirin showed comparable activity against these viruses. SP-303 also exhibits significant inhibitory activity against herpesvirus (HSV) types 1 and 2, including herpesviruses resistant to acyclovir and foscarnet. Inhibition was also observed against hepatitis A and B viruses. The antiviral mechanism of SP-303 seems to derive from its direct binding to components of the viral envelope, resulting in inhibition of viral attachment and penetration of the plasma membrane. Antiviral effects of SP-303 were measured by three distinct methods: CPE, MTT and precursor uptake/incorporation. Cytotoxicity endpoints were markedly greater than the respective antiviral endpoints. SP-303 exhibited activity in RSV-infected cotton rats and African green monkeys, PIV-3-infected cotton rats, HSV-2 infected mice and guinea pigs and FLU-A-infected mice. The most successful routes of SP-303 administration for producing efficacy were: topical application to HSV-2- genital lesions in mice and guinea pigs, aerosol inhalation to FLU-A-infected mice and PIV-3-infected cotton rats, and oral dosage to RSV-infected cotton rats. A variety of toxicological evaluations demonstrated the safety of SP-303, particularly orally, which was predictable, since condensed tannins are a common dietary component. It is notable that the larger proanthocyanidins as a class have high antiviral activity, whereas most of the monomers are inactive. Clinical trials are ongoing to evaluate SP-303 as a therapeutic antiviral agent.
authors.affiliation: Shaman Pharmaceuticals, 213 East Grand Avenue, South San Francisco, CA 94080-4812, U.S.A.
authors.forename: R
authors.initials: R
authors.lastname: Ubillas
authors.forename: S D
authors.initials: SD
authors.lastname: Jolad
authors.forename: R C
authors.initials: RC
authors.lastname: Bruening
authors.forename: M R
authors.initials: MR
authors.lastname: Kernan
authors.forename: S R
authors.initials: SR
authors.lastname: King
authors.forename: D F
authors.initials: DF
authors.lastname: Sesin
authors.forename: M
authors.initials: M
authors.lastname: Barrett
authors.forename: C A
authors.initials: CA
authors.lastname: Stoddart
authors.forename: T
authors.initials: T
authors.lastname: Flaster
authors.forename: J
authors.initials: J
authors.lastname: Kuo
authors.forename: F
authors.initials: F
authors.lastname: Ayala
authors.forename: E
authors.initials: E
authors.lastname: Meza
authors.forename: M
authors.initials: M
authors.lastname: Castañel
authors.forename: D
authors.initials: D
authors.lastname: McMeekin
authors.forename: E
authors.initials: E
authors.lastname: Rozhon
authors.forename: M S
authors.initials: MS
authors.lastname: Tempesta
authors.forename: D
authors.initials: D
authors.lastname: Barnard
authors.forename: J
authors.initials: J
authors.lastname: Huffman
authors.forename: D
authors.initials: D
authors.lastname: Smee
authors.forename: R
authors.initials: R
authors.lastname: Sidwell
authors.forename: K
authors.initials: K
authors.lastname: Soike
authors.forename: A
authors.initials: A
authors.lastname: Brazier
authors.forename: S
authors.initials: S
authors.lastname: Safrin
authors.forename: R
authors.initials: R
authors.lastname: Orlando
authors.forename: P T
authors.initials: PT
authors.lastname: Kenny
authors.forename: N
authors.initials: N
authors.lastname: Berova
authors.forename: K
authors.initials: K
authors.lastname: Nakanishi